Including persons with Alzheimer disease in research on comorbid conditions

IRB Ethics and Human Research

Volumn 31, Issue 1, 2009, Pages 1-6

  Wall, Anji ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; COMORBIDITY; ETHICS; HUMAN; MEDICAL RESEARCH; PATIENT SELECTION; PROFESSIONAL STANDARD; RESEARCH ETHICS; SOCIAL JUSTICE; STANDARD; UNITED STATES;

ALZHEIMER DISEASE; BIOMEDICAL RESEARCH; COMORBIDITY; ETHICS COMMITTEES, RESEARCH; ETHICS, RESEARCH; HUMANS; PATIENT SELECTION; SOCIAL JUSTICE; UNITED STATES;

EID: 60149092192     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Grossman H, Bergmann C, Parker S. Dementia: A brief review. Mount Sinai Journal of Medicine 2006;73(7):985-992.
2. Desai AK, Grossberg GT. Diagnosis and treatment of Alzheimer's disease. Neurology 2005;64(12 Suppl 3):S34-39.
3. See ref. 1, Grossman et al. 2006.
4. Cummings JL et al. Guidelines for managing Alzheimer's disease part I: Assessment. American Family Physician 2002;65(11): 2263-2272.
5. Dresser R. Research involving persons with mental disabilities: A review of policy issues and proposals. In: National Bioethics Advisory Commission. Research Involving Persons with Mental Disorders That May Affect Decisionmaking Capacity. Volume II: Commissioned Papers, 1998; Moreno JD. Critical issues concerning research involving decisionally impaired persons. In: National Bioethics Advisory Commission. Research Involving Persons with Mental Disorders That May Affect Decisionmaking Capacity. Volume II: Commissioned Papers, 1998; Post SG. Why the tolerance of potential harms? Research ethics in Alzheimer disease. Accountability in Research 1999;7(2-4):241-253;
6. Post SG. Full-spectrum proxy consent for research participation when persons with Alzheimer disease lose decisional capacities: Research ethics and the common good. Alzheimer Disease and Associated Disorders 2003;17 Suppl 1:S3-11.
7. See ref. 5, Post 2003; Karlawish JH et al. Informed consent for Alzheimer's disease clinical trials: A survey of clinical investigators. IRB: Ethics & Human Research 2002;24(5):1-5;
8. Stocking CB et al. Ethics reporting in publications about research with Alzheimer's disease patients. Journal of the American Geriatric Society 2004;52(2):305-310;
9. Stocking CB et al. Are the rules for research with subjects with dementia changing? Views from the field. Neurology 2003;61(12):1649-1651.
10. See ref. 2, Desai and Grossberg 2005; See ref. 4, Cummings et al. 2002.
11. Backman L et al. Rate of cognitive decline in preclinical Alzheimer's disease: The role of comorbidity. Journals of Gerontology Series B: Psychological Sciences and Social Sciences 2003;58(4):P228-236.
12. See ref. 2, Desai and Grossberg 2005;
13. See ref. 4, Cummings et al. 2002.
14. Zamrini E et al. Medical comorbidity in black and white patients with Alzheimer's disease. Southern Medical Journal 2004;97(1):2-6;
15. Doraiswamy PM et al. Prevalence and impact of medical comorbidity in Alzheimer's disease. Journal of Gerontology Series A: Biological Sciences and Medical Sciences 2002;57(3):M173-177;
16. Sanderson M et al. Comorbidity associated with dementia. American Journal of Alzheimers Disease and Other Dementias 2002;17(2):73-78.
17. Lyketsos CG et al. Treating depression in Alzheimer disease: Efficacy and safety of sertraline therapy, and the benefits of depression reduction: The DIADS. Archives of General Psychiatry 2003;60(7):737-746;
18. Rosenberg PB, Mielke MM, Lyketsos CG. Caregiver assessment of patients' depression in Alzheimer disease: Longitudinal analysis in a drug treatment study. American Journal of Geriatric Psychiatry 2005;13(9):822-826.
19. Moretti R et al. Depression and Alzheimer's disease: Symptom or comorbidity? American Journal of Alzheimers Disease and Other Dementias 2002;17(6):338-344.
20. Hill JW et al. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology 2002;58(1):62-70;
21. Fillit H, Hill JW, Futterman R. Health care utilization and costs of Alzheimer's disease: The role of comorbid conditions, disease stage, and pharmacotherapy. Family Medicine 2002;34(7):528-535;
22. Allan LM et al. Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias. Journal of the American Geriatric Society 2005;53(10):1681-1687.
23. See ref. 13, Hill et al. 2002.
24. See ref. 13, Hill et al. 2002;
25. Sloan FA, Taylor DH, Jr. Effect of Alzheimer disease on the cost of treating other diseases. Alzheimer Disease and Associated Disorders 2002;16(3): 137-143.
26. Larson EB et al. Survival after initial diagnosis of Alzheimer disease. Annals of Internal Medicine 2004;140(7):501-509.
27. Tschanz JT et al. Dementia: The leading predictor of death in a defined elderly population: The Cache County Study. Neurology 2004;62(7):1156-1162.
28. Kipnis K. Vulnerability in research subjects: A bioethical taxonomy. In: National Bioethics Advisory Commission. Ethical and Policy Issues in Research Involving Human Participants. Volume II: Commissioned Papers and Staff Analysis, 2001.
29. The Nuremberg Code, http://ohsr.od. nih.gov/guidelines/nuremberg.html; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: Government Printing Office, 1979.
30. Berg JW, Appelbaum PS. Informed Consent: Legal Theory and Clinical Practice. 2nd ed. Oxford, U.K.: Oxford University Press, 2001.
31. See ref. 19, National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 1979.
32. Department of Health and Human Services. Protection of Human Subjects. 45 CFR 46; Food and Drug Administration. Protection of Human Subjects, 21 CFR 50.
33. The Alzheimer's Association. Ethical Issues in Dementia Research, 2007. http://www.alz.org/national/documents/statements_ethicalissues.pdf.
34. Sachs GA. American Geriatrics Society Position Statement Informed Consent for Research on Human Subjects with Dementia, 2007.
35. National Bioethics Advisory Commission. Research Involving Persons with Mental Disorders That May Affect Decisionmaking Capacity. Volume I, 1998. More recently, the Secretary's Advisory Committee for Human Research Protections has been investigating whether the Department of Health and Human Services should issue guidance and/or additional regulations for research involving individuals with impaired decision-making capacity. See the Subcommittee on Inclusion of Individuals with Impaired Decision-Making in Research (SII-IDR), http://www.hhs.gov/ohrp/sachrp/subcommittees.html
36. Bravo G, Dubois MF, Paquet M. Advance directives for health care and research: Prevalence and correlates. Alzheimer Disease and Associated Disorders 2003;17(4): 115-2.2.1.
37. See ref. 25, The National Bioethics Advisory Commission 1998.
38. See ref. 24, Sachs 2007.
39. See ref. 5, Moreno 1998.
40. See ref. 23, The Alzheimer's Association 2007.
41. See ref. 5, Post 1999.
42. See ref. 19, National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 1979.
43. List JM. Histories of mistrust and protectionism: Disadvantaged minority groups and human-subject research policies. The American Journal of Bioethics 2005;5(1):53-56; author reply W15-8.
44. See ref. 33, List 2005.
45. See ref. 33, List 2005.
46. Weijer C. Selecting subjects for participation in clinical research: One sphere of justice. Journal of Medical Ethics 1999;25(1):31-36.
47. Brody BA. The Ethics of Biomedical Research: An International Perspective. New York: Oxford University Press, 1998.
48. See ref. 2, Desai and Grossberg 2005.